Clinical Trials Browser

Phase 3 × Myasthenia Gravis × 30 days × Clear all

NCT06463587 2026-03-19

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Phase 3 Recruiting

Myasthenia Gravis

NCT07463521 2026-03-17

MyVision

Phase 3 Not yet recruiting

Myasthenia Gravis

NCT06607627 2026-03-16

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Phase 3 Recruiting

Myasthenia Gravis

NCT06435312 2026-03-13

ziMyG+

Phase 3 Enrolling by invitation

Myasthenia Gravis

NCT07217587 2026-03-13

EPIC

Phase 3 Recruiting

Myasthenia Gravis

NCT07465289 2026-03-11

A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

Phase 3 Not yet recruiting

Myasthenia Gravis

NCT04524273 2026-03-10

MINT

Phase 3 Active not recruiting

238 enrolled 36 charts

Myasthenia Gravis

NCT06456580 2026-03-10

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Phase 3 Recruiting

Myasthenia Gravis

NCT05403541 2026-03-06

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Phase 3 Active not recruiting

Myasthenia Gravis

NCT07039916 2026-03-06

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Phase 3 Recruiting

Autoimmune Diseases, Myasthenia Gravis

NCT04951622 2026-03-03

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Phase 3 Recruiting

199 enrolled 11 charts

Myasthenia Gravis

NCT06540144 2026-02-27

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Phase 3 Enrolling by invitation

Myasthenia Gravis

NCT06517758 2026-02-24

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Phase 3 Recruiting

Myasthenia Gravis

NCT07215949 2026-02-23

Zilucoplan for Severe gMG Exacerbations

Phase 3 Recruiting

Myasthenia Gravis

NCT06744920 2026-02-20

RELIEVE

Phase 3 Recruiting

Myasthenia Gravis

NCT05644561 2026-02-19

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)

Phase 3 Active not recruiting

Myasthenia Gravis